Pulmonx publishes investor presentation on Zephyr valves for severe emphysema treatment

• Pulmonx outlined a severe emphysema total addressable market of about USD 12 billion, citing about 1.2 million eligible collateral ventilation-negative patients in major markets.
• 1Q26 revenue totaled USD 20.6 million, including USD 13.3 million in U.S. revenue, USD 7.3 million outside U.S. revenue.
• Gross margin measured 78% in 1Q26.
• Cash, cash equivalents, and marketable securities totaled USD 61.6 million as of 3/31/2026.
• Pipeline update highlighted AeriSeal as an investigational bronchoscopic foam intended to convert some collateral ventilation-positive patients to enable subsequent Zephyr valve treatment, targeting at least a 20% expansion in addressable market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.